source
- Freenome colorectal cancer test data improve on earlier resultsThe new study results could make Abbott, which has an agreement with Freenome to market the blood-based test, the dominant player in colorectal cancer screening, Evercore ISI analysts said.BioPharma Dive · 17d ago↗ source
- FDA proposes rule to simplify drugmakers' factory registrationsThe FDA is proposing a rule to change how factories are registered with the agency if they are making products for the US market, as part of a continuing effort to try to speed up ...Endpoints · 17d ago↗ source
- Q32 bounces back to claim study success for alopecia drugNearly two years after clinical setbacks cratered Q32’s stock price, new results showed hair growth improvements that surpassed investors’ expectations.